Product Overview: Helios
Helios 80mcg clenbuterol + 10.8mg yohimbine is a dual-component research formulation combining a beta-2 adrenergic receptor agonist with an alpha-2 adrenergic receptor antagonist. This DNA Labs preparation enables researchers to investigate synergistic metabolic pathways and adrenergic receptor interactions in controlled laboratory environments. The formulation provides standardised concentrations for consistent experimental protocols when examining lipolytic mechanisms and thermogenic responses in cellular models.
Laboratory Applications
Researchers at Stroid UK Shop utilise this compound combination to examine beta-adrenergic signalling cascades and their metabolic effects in adipocyte cultures. The clenbuterol component allows investigation of beta-2 receptor activation and cyclic adenosine monophosphate (cAMP) elevation, while yohimbine enables studies of alpha-2 receptor antagonism and noradrenergic modulation. Scientists examining metabolic research can explore this formulation alongside other compounds from our specialised metabolic modulators, selective androgen receptor modulators, and bioactive peptides to establish comprehensive experimental protocols. The dual-mechanism approach facilitates research into thermogenesis, lipolysis, and adrenergic receptor cross-talk in various tissue models.
Technical Specifications
| Parameter | Specification |
|---|---|
| Clenbuterol Content | 80 mcg per unit |
| Yohimbine HCl Content | 10.8 mg per unit |
| Manufacturer | DNA Labs |
| Form | Injectable solution |
| Storage Requirements | 2-8°C, protect from light |
| Molecular Formulas | C₁₂H₁₈Cl₂N₂O (clen) / C₂₁H₂₆N₂O₃ (yohimbine) |
Research Compliance
This Helios formulation is manufactured exclusively for in-vitro research applications and laboratory analysis. Not intended for human consumption, veterinary use, or any diagnostic purposes. Researchers must maintain appropriate laboratory protocols and safety measures when handling this dual-component preparation for adrenergic receptor studies and metabolic pathway investigations.
